By Josh White
Date: Thursday 09 May 2024
(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.
By Iain Gilbert
Date: Thursday 08 Feb 2024
(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.
By Josh White
Date: Thursday 16 Nov 2023
(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.
Currency | UK Pounds |
Share Price | 109.00p |
Change Today | -1.20p |
% Change | -1.09 % |
52 Week High | 162.20 |
52 Week Low | 106.20 |
Volume | 130,822 |
Shares Issued | 651.27m |
Market Cap | £709.88m |
RiskGrade | 291 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
Latest | Previous | |
---|---|---|
Final | Final | |
Ex-Div | 21-Jun-18 | 20-Jul-17 |
Paid | 30-Jul-18 | 23-Aug-17 |
Amount | 2.30p | 2.30p |
Time | Volume / Share Price |
09:30 | 25,000 @ 109.40p |
09:30 | 25,000 @ 109.40p |
09:29 | 25,000 @ 109.40p |
09:28 | 1,452 @ 109.64p |
09:23 | 14,000 @ 109.00p |
You are here: research